Advertisement

Topics

Companies Related to "A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotheraphy in Locally Advanced Adenocarcinoma of the Rectum" [Most Relevant Company Matches] - Page: 2 RSS

22:03 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotheraphy in Locally Advanced Adenocarcinoma of the Rectum" found in our extensive corporate database of over 50,000 company records.

Showing "Phase Study AZD6244 Combination With Capecitabine Radiotheraphy Locally" Companies 26–50 of 1,600+

Relevant

Atlantic Life Sciences, Inc

Atlantic Life Sciences, Inc., Provider of Tailored Clinical Services ALS Inc. is located in Montreal.It is one of the world-class CRO where the Experience, the Expertise and the Strategic Project Management create a value addition for the study success. Since its inception, Atlantic Life Sciences Inc. accomplishes clinical studies with a top quality. Each study is unique. Since 2003, ALS Inc. cond...


Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product, CORLUX, is currently in three Phase 3 clinical trials for the treatment of the psychotic features of psychotic major depression (PMD), a disorder that affects approximately three million adults in the United States ea...

Immunovaccine Inc.

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials ...


PHAROS GmbH

PHAROS GmbH is a Contract Research Organisation for Early Clinical Research and various related services. All of our services are custom designed, thus these pages are only a guide to the types of services we are able to offer.Our main services are:Clinical Trial Services• Phase I Study Services• Bioequivalence Study Services• Clinical Trial Elements and ProceduresQuality Management Services...

The National Stroke Research Institute

The National Stroke Research Institute is directed by Professor Geoffrey Donnan. The NSRI has played a key role in national and international trials of treatment for stroke which have greatly improved services. In addition, the Institute has completed the initial phase of the North East Melbourne Stroke Incidence Study (NEMESIS) in Melbourne. The results from the study will teach us a lot about th...

Bio-Kinetic Clinical Applications

Bio-Kinetic Clinical Applications, the choice for your next Phase I study, is located in Springfield, MO. Founded in 1994 by Dale Bourg and Dave Koenigsfeld, BKCA has grown from a 12 bed facility to its current capacity of 132 beds. Expansion plans are in place to increase capacity to 240 beds by the fall of 2006. We also have an established relationship with Bio-Kinetic Europe located in Belfast...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and are developing scientifically and clinically validated over the counter and prescription products that utilize TFS’ cultivated, sustainable, pharmaceutical-grade East Indian S...

Hanmi Pharmaceutical co., Ltd.

Hanmi Pharmaceutical is a Korea-based pharmaceutical company. The Company invests over 20 percent of its sales in R&D and has over 20 programs consisting of the novel long acting biologics including weekly Insulin, weekly to monthly GLP-1, and their combination for diabetes and obesity (collectively referred as Quantum Project), the novel targeted anti-can...

Inflazyme Pharmaceuticals Ltd.

Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of respiratory and inflammatory diseases. Our core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.Our most advanced product, IPL512,602, is on track to enter a phase IIb clinical stud...

Neuro-Hitech

Neuro-Hitech is focused specifically on the development and commercialization of next-generation therapies against proven targets for neurodegenerative diseases. The company’s signature offering, Huperzine A is being tested for efficacy in the treatment of Alzheimer's disease and the company has plans to study other degenerative disorders such as vascular dementia, mild cognitive impairment and ...

CEL-SCI Corporation CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the h...

Urigen Holdings Inc

Urigen is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen has five products in development for urology indications that are either in or positioned to enter Phase 2 clinical trials. The pipeline includes U101, for which a Phase 2b study in on-going for the treatment of Chronic Pelvic Pain (CPP); U102, ta...

Axonyx

Axonyx is a biopharmaceutical company focused on the acquisition and development of proprietary products and technologies for the treatment and diagnosis of Alzheimer's Disease and other memory-related cognitive disorders including prion diseases such as Mad Cow Disease. After completion of a Phase II Proof of Concept clinical study in October of 2001 for Phenserine, Axonyx's lead product for Alzh...

DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a comm...

KLIXAR

KLIXAR is a locally owned Contract Research Organization (CRO) located in Latin America combining the advantages of an agile company with those of a big international one. We offer clinical drug development and consulting services (specializing in Phase II to IV) aimed to serve the needs of small to medium size clinical trials. Sponsors in the pharmaceutical and biotechnology industry as well as ...

Advanced Biomedical Research Incorporated

Advanced Biomedical Research, Inc. (ABR) Corporate Headquarters is located in Pennington, New Jersey adjacent to the Princeton biopharmaceutical research corridor. ABR is a full service CRO offering an integrated package of customized services including clinical study protocol design, project management and study monitoring, quality assurance auditing, medical safety monitoring, biostatistics and...

Carbylan BioSurgery, Inc.

Carbylan (www.carbylan.com) was founded in 2005 to develop and market medical devices and device/drug combination products based on novel chemically engineered polymer systems incorporating hyaluronic acid, a well-known polysaccharide widely present in the human body. Its initial market focus is therapeutic medical devices and combination products to treat...

Soligenix, Inc.

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec(®) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute ...

Rapid Medical Research, Inc.

Rapid Medical Research, Inc., (RMR) is a free-standing, dedicated, multi-therapeutic clinical research center. Our professional research team includes an executive director, two physicians including a full-time onsite internist and 1 part-time OB/GYN, a regulatory specialist, four nurse coordinators, two patient recruiters, two research assistants, and an office manager. We offer a wide range of s...

Adamis Pharmaceuticals Corporation

La Jolla Pharmaceutical Company is a biopharmaceutical company. La Jolla had historically focused substantially all of its research, development and clinical efforts and financial resources toward the development of its Riquent® (abetimus sodium) product candidate, as a treatment for patients with lupus. In February 2009, La Jolla announced that an inde...

bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

ARCH Clinical Research

ARCH Clinical Research provides pharmaceutical and biotechnology companies with high-quality clinical research services in Australia and New Zealand. In a time- and cost-efficient manner and according to the clients' exact needs, we can assist with completing the entire study or any segment, including: clinical study design, monitoring and management, data management and biostatistics, regulatory ...

DP Clinical

DP Clinical is a privately-held, minority-owned contract research organization (CRO) located in the I-270 Technology Corridor in Rockville, Maryland serving pharmaceutical and biotechnology clients. Providing our clients with monitoring, data management, analysis, and biostatistics for Phase I – IV clinical trials, DP Clinical has built a strong reputation for high standards of quality, data int...

Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. (NASDAQ-PPHM) is a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection. The Company is advancing three separate clinical programs with its lead product candidates bavituximab and Cotara®. Bavituximab and Cotara are both in Phase II clinical studies for the treatment o...

Phase One Medical, L.L.C.

Phase One Medical is a privately held medical device research and development company. The company is focused on early stage development and small part design and manufacture. For more information on Phase One Medical, L.L.C. products and services e-mail the company at info@phase-one.us.


More From BioPortfolio on "A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotheraphy in Locally Advanced Adenocarcinoma of the Rectum"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks